Excellent Response with Ado-Trastuzumab Emtansine in a Patient with Relapsed Metastatic Breast Cancer Presenting with Pulmonary Lymphangitic Carcinomatosis

In breast cancer, aggressive tumor biology and the corresponding poor prognosis is associated with amplification or overexpression of the human epidermal growth factor receptor 2 (HER2). Trastuzumab has significantly changed the natural history of HER2-positive breast cancer. However, resistance to...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Zhou, Sankar, Shobana, Huben, Marianne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2017
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5598866/
https://www.ncbi.nlm.nih.gov/pubmed/28944112
http://dx.doi.org/10.7759/cureus.1473

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5598866/
https://www.ncbi.nlm.nih.gov/pubmed/28944112
http://dx.doi.org/10.7759/cureus.1473

Ejemplares similares